* CELLVAX *
2001 - IDF
Évry
(near Paris)
www.cellvax-pharma.com Contract, Services
Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model
Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field
Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II)
contact@cellvax-pharma.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology]
Sc.Dir.-CSO: Wei (Ming)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
Note : webhosting with Lycos withdrawn in March 2009 | Turnover (M€) : 0.22 (2007), 0.28 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cancers
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .00 | Certification : Eureka award on Oligoclonics | INFO | [5 years] |
| 2001 .06 | Company founded by Ming Wei, 2 other biologists, Christian Schatz [Pharm.D.], Olivier-Noël Martin [ex-Sterilyo, founder], and Michel Crépin | ORGF | [0 year] | Actualisation / Updating: 11-Sept-2009 |
|
